{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:30:04Z","timestamp":1780489804038,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00198-024-07161-x","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T05:01:50Z","timestamp":1721710910000},"page":"1919-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Borowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Strzelecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Budlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Janowska-Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-574X","authenticated-orcid":false,"given":"Krzysztof","family":"Szymanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kwiatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Postol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"P\u00f5der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungHyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeeHye","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NooRi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NaHyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeoHee","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5313-1018","authenticated-orcid":false,"given":"Stuart L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"7161_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609","journal-title":"J Orthop Surg Res"},{"key":"7161_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstr\u00f6m","year":"2020","unstructured":"Borgstr\u00f6m F, Karlsson L, Orts\u00e4ter G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59","journal-title":"Arch Osteoporos"},{"key":"7161_CR3","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1007\/s00198-022-06482-z","volume":"33","author":"U Tarantino","year":"2022","unstructured":"Tarantino U, Cariati I, Greggi C et al (2022) Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. Osteoporos Int 33:2467\u20132478","journal-title":"Osteoporos Int"},{"key":"7161_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","volume":"55","author":"SA Williams","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55:821\u2013829","journal-title":"Ann Pharmacother"},{"key":"7161_CR5","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell R, O\u2019Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069","journal-title":"Nat Rev Dis Primers"},{"key":"7161_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","volume":"35","author":"ED Deeks","year":"2018","unstructured":"Deeks ED (2018) Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35:163\u2013173","journal-title":"Drugs Aging"},{"key":"7161_CR7","unstructured":"Amgen Inc. (2024) Prolia\u00ae: prescribing information.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125320s216lbl.pdf. Accessed 26 Jun 2024"},{"key":"7161_CR8","unstructured":"Amgen Europe BV (2020) Prolia\u00ae: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf. Accessed 26 Jun 2024"},{"key":"7161_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00198-021-06291-w","volume":"33","author":"EC-C Lai","year":"2022","unstructured":"Lai EC-C, Lin T-C, Lange JL, Chen L, Wong ICK, Sing CW, Cheung CL, Shao SC, Yang YK (2022) Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. Osteoporos Int 33:1155\u20131164","journal-title":"Osteoporos Int"},{"key":"7161_CR10","doi-asserted-by":"publisher","first-page":"588095","DOI":"10.3389\/fphar.2021.588095","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhu J, Zhou Y, Peng J, Wang B (2021) Efficacy and safety of denosumab in osteoporosis or low bone mineral density postmenopausal women. Front Pharmacol 12:588095","journal-title":"Front Pharmacol"},{"key":"7161_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7161_CR12","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V (2022) The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum 52:151939","journal-title":"Semin Arthritis Rheum"},{"key":"7161_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000496834","volume":"14","author":"A Busse","year":"2019","unstructured":"Busse A, L\u00fcftner D (2019) What does the pipeline promise about upcoming biosimilar antibodies in oncology? Breast Care (Basel) 14:10\u201316","journal-title":"Breast Care (Basel)"},{"key":"7161_CR14","doi-asserted-by":"publisher","first-page":"104467","DOI":"10.1016\/j.phrs.2019.104467","volume":"149","author":"FC Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo FC, Gon\u00e7alves J, Fonseca JE (2019) Biosimilars in rheumatology. Pharmacol Res 149:104467","journal-title":"Pharmacol Res"},{"key":"7161_CR15","unstructured":"US Food and Drug\u00a0Administration\u00a0(2024) FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and. Accessed 26 Jun 2024"},{"key":"7161_CR16","unstructured":"European Pharmaceutical Review (2024) European Commission grants first-of-a-kind biosimilar approval By Catherine Eckford. News. https:\/\/www.europeanpharmaceuticalreview.com\/news\/229320\/european-commission-grants-first-of-a-kind-biosimilar-approval\/"},{"key":"7161_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi A, Vojdanian M, Soroush M et al (2022) Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther 24:161","journal-title":"Arthritis Res Ther"},{"key":"7161_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","volume":"44","author":"H Zhang","year":"2023","unstructured":"Zhang H, Gu J-M, Chao A-J et al (2023) A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin 44:446\u2013453","journal-title":"Acta Pharmacol Sin"},{"key":"7161_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jot.2022.06.007","volume":"38","author":"J Gu","year":"2022","unstructured":"Gu J, Zhang H, Xue Q et al (2022) Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study. J Orthop Translat 38:117\u2013125","journal-title":"J Orthop Translat"},{"key":"7161_CR20","first-page":"1","volume":"22","author":"A Kim","year":"2024","unstructured":"Kim A, Hong JH, Shin W et al (2024) A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT-P41 and reference denosumab in healthy males. Expert Opin Biol Ther 22:1\u20139","journal-title":"Expert Opin Biol Ther"},{"key":"7161_CR21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force (2018) Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA 319:2521\u20132531","journal-title":"JAMA"},{"key":"7161_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"7161_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"7161_CR24","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149\u20132157","journal-title":"J Clin Endocrinol Metab"},{"key":"7161_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537","journal-title":"J Bone Miner Res"},{"key":"7161_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.33176\/AACB-20-0001","volume":"42","author":"MJ Gillett","year":"2021","unstructured":"Gillett MJ, Vasikaran SD, Inderjeeth CA (2021) The role of PINP in diagnosis and management of metabolic bone disease. Clin Biochem Rev 42:3\u201310","journal-title":"Clin Biochem Rev"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07161-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:02:39Z","timestamp":1729677759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07161-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7161"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07161-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to Good Clinical Practice, the principles of the Declaration of Helsinki, and national, state, and local laws or regulations. Study materials were approved by independent ethics committees\/institutional review boards at each site (Supplementary Table\u00a0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"JY-R consults for Celltrion, Inc. EC has received funding from Celltrion, Inc. for his role as an investigator in this study and honoraria for lectures from Amgen. PB has received funding from Celltrion, Inc. for his role as an investigator in this study and honoraria for speaker events and authorship on patient materials from Amgen, AstraZeneca, and Pierre Fabre. KW, KS, AP, AS, JK, JS, MJM, SP, and TB have received funding from Celltrion, Inc. for their role as investigators in this study. SLS has received grants from Amgen and Tissuegene, and consults for Celltrion, Inc. JHS, NRH, NHK, and SHB are employees of and own stock in Celltrion, Inc. SHK is an employee of Celltrion, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}